Please login to the form below

Not currently logged in
Email:
Password:

tildrakizumab

This page shows the latest tildrakizumab news and features for those working in and with pharma, biotech and healthcare.

Latecomer Lilly preps its IL-23 drug for Crohn’s disease

Latecomer Lilly preps its IL-23 drug for Crohn’s disease

Stelara has since been joined by J&J’s follow-up IL-23 inhibitor Tremfya (guselkumab), Sun Pharma’s Ilumya (tildrakizumab) and AbbVie/Boehringer Ingelheim’s Skyrizi (risankizumab), which are all

Latest news

More from news
Approximately 1 fully matching, plus 7 partially matching documents found.

Latest Intelligence

  • Deal Watch July 2016 Deal Watch July 2016

    Almirall paid $50m upfront to Sun Pharma for a licence to tildrakizumab (an IL-23p19 antibody) in Europe, and the deal includes payments of undisclosed development and regulatory milestones as well ... Acquisition. 78. Sun Pharma/ Almirall. Tildrakizumab

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Jet Off with Maloff Protect

Latest intelligence

Theodora Harold
A snapshot of Crescendo Biologics
PME talks to CEO Theodora Harold...
eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...
US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...

Infographics